http://www.tkuhn.ch/bel2nanopub/RA20l50oS1xVwEOyXFwn0Y1F3Sax31GfaL6JyEZ74yRJY#Head http://www.tkuhn.ch/bel2nanopub/RA20l50oS1xVwEOyXFwn0Y1F3Sax31GfaL6JyEZ74yRJY http://www.nanopub.org/nschema#hasAssertion http://www.tkuhn.ch/bel2nanopub/RA20l50oS1xVwEOyXFwn0Y1F3Sax31GfaL6JyEZ74yRJY#assertion http://www.tkuhn.ch/bel2nanopub/RA20l50oS1xVwEOyXFwn0Y1F3Sax31GfaL6JyEZ74yRJY http://www.nanopub.org/nschema#hasProvenance http://www.tkuhn.ch/bel2nanopub/RA20l50oS1xVwEOyXFwn0Y1F3Sax31GfaL6JyEZ74yRJY#provenance http://www.tkuhn.ch/bel2nanopub/RA20l50oS1xVwEOyXFwn0Y1F3Sax31GfaL6JyEZ74yRJY http://www.nanopub.org/nschema#hasPublicationInfo http://www.tkuhn.ch/bel2nanopub/RA20l50oS1xVwEOyXFwn0Y1F3Sax31GfaL6JyEZ74yRJY#pubinfo http://www.tkuhn.ch/bel2nanopub/RA20l50oS1xVwEOyXFwn0Y1F3Sax31GfaL6JyEZ74yRJY http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://www.tkuhn.ch/bel2nanopub/RA20l50oS1xVwEOyXFwn0Y1F3Sax31GfaL6JyEZ74yRJY#assertion http://www.tkuhn.ch/bel2nanopub/RA20l50oS1xVwEOyXFwn0Y1F3Sax31GfaL6JyEZ74yRJY#_1 http://purl.obolibrary.org/obo/RO_0002204 http://www.genenames.org/cgi-bin/gene_symbol_report?hgnc_id=2432 http://www.tkuhn.ch/bel2nanopub/RA20l50oS1xVwEOyXFwn0Y1F3Sax31GfaL6JyEZ74yRJY#_1 http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI_36080 http://www.tkuhn.ch/bel2nanopub/RA20l50oS1xVwEOyXFwn0Y1F3Sax31GfaL6JyEZ74yRJY#_2 http://purl.obolibrary.org/obo/BFO_0000066 http://purl.obolibrary.org/obo/CL_0000115 http://www.tkuhn.ch/bel2nanopub/RA20l50oS1xVwEOyXFwn0Y1F3Sax31GfaL6JyEZ74yRJY#_2 http://purl.obolibrary.org/obo/BFO_0000066 http://purl.obolibrary.org/obo/UBERON_0001621 http://www.tkuhn.ch/bel2nanopub/RA20l50oS1xVwEOyXFwn0Y1F3Sax31GfaL6JyEZ74yRJY#_2 http://purl.obolibrary.org/obo/BFO_0000066 http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=9606 http://www.tkuhn.ch/bel2nanopub/RA20l50oS1xVwEOyXFwn0Y1F3Sax31GfaL6JyEZ74yRJY#_2 http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://www.tkuhn.ch/bel2nanopub/RA20l50oS1xVwEOyXFwn0Y1F3Sax31GfaL6JyEZ74yRJY#_1 http://www.tkuhn.ch/bel2nanopub/RA20l50oS1xVwEOyXFwn0Y1F3Sax31GfaL6JyEZ74yRJY#_2 http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate http://www.selventa.com/vocabulary/decreases http://www.tkuhn.ch/bel2nanopub/RA20l50oS1xVwEOyXFwn0Y1F3Sax31GfaL6JyEZ74yRJY#_2 http://www.w3.org/1999/02/22-rdf-syntax-ns#subject http://www.ebi.ac.uk/chebi/searchId.do?chebiId=503465 http://www.tkuhn.ch/bel2nanopub/RA20l50oS1xVwEOyXFwn0Y1F3Sax31GfaL6JyEZ74yRJY#_2 http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://www.tkuhn.ch/bel2nanopub/RA20l50oS1xVwEOyXFwn0Y1F3Sax31GfaL6JyEZ74yRJY#assertion http://www.w3.org/2000/01/rdf-schema#label a(CHEBI:cerivastatin) -| p(HGNC:CSF1) http://www.tkuhn.ch/bel2nanopub/RA20l50oS1xVwEOyXFwn0Y1F3Sax31GfaL6JyEZ74yRJY#provenance http://resource.belframework.org/belframework/20131211/knowledge/large_corpus.bel http://purl.org/dc/elements/1.1/description Approximately 61,000 statements. http://resource.belframework.org/belframework/20131211/knowledge/large_corpus.bel http://purl.org/dc/elements/1.1/rights Copyright (c) 2011-2012, Selventa. All rights reserved. http://resource.belframework.org/belframework/20131211/knowledge/large_corpus.bel http://purl.org/dc/elements/1.1/title BEL Framework Large Corpus Document http://resource.belframework.org/belframework/20131211/knowledge/large_corpus.bel http://purl.org/pav/authoredBy http://www.tkuhn.ch/bel2nanopub/RA20l50oS1xVwEOyXFwn0Y1F3Sax31GfaL6JyEZ74yRJY#_5 http://resource.belframework.org/belframework/20131211/knowledge/large_corpus.bel http://purl.org/pav/version 20131211 http://www.tkuhn.ch/bel2nanopub/RA20l50oS1xVwEOyXFwn0Y1F3Sax31GfaL6JyEZ74yRJY#_3 http://purl.org/dc/elements/1.1/identifier AHA Abstracts 1516 http://www.tkuhn.ch/bel2nanopub/RA20l50oS1xVwEOyXFwn0Y1F3Sax31GfaL6JyEZ74yRJY#_3 http://purl.org/dc/elements/1.1/title AHA Abstracts 1516 http://www.tkuhn.ch/bel2nanopub/RA20l50oS1xVwEOyXFwn0Y1F3Sax31GfaL6JyEZ74yRJY#_3 http://purl.org/dc/elements/1.1/type Other http://www.tkuhn.ch/bel2nanopub/RA20l50oS1xVwEOyXFwn0Y1F3Sax31GfaL6JyEZ74yRJY#_4 http://www.w3.org/ns/prov#value Background: Beneficial effects of HMG-CoA reductase inhibitors were initially attributed to the effects on serum cholesterol levels. However, recent evidence suggests that statins may have vascular benefits independent of cholesterol lowering. To determine if statins have direct effects on vascular endothelium, we examined the effects of cerivastatin and pravastatin on tumor necrosis factor (TNF-? and oxidized low density lipoprotein (Ox-LDL)-induced endothelial cell expression of macrophage-colony stimulating factor (M-CSF), a molecule that importantly contributes to the pathogenesis of atherosclerosis. Methods and Results: Human coronary artery endothelial cells (HCAECs) were treated with (TNF)-? (10 ng/ml) or Ox-LDL (100 ?g/ml, thiobarbituric acid reactive substances ranging from 2.6 to 13.4 nmol/mg of LDL protein) in the absence or presence of cerivastatin (1 ?M) and pravastatin (50 ?M). Expression of M-CSF was examined by RNA- and protein- based assays. Both TNF-? and Ox-LDL increased M-CSF mRNA levels (5-fold after 8 hours) and protein levels (4.1-fold induction after 48 hours). Statins downregulated both steady state and TNF-? or Ox-LDL-induced M-CSF mRNA and protein levels in HCAECs. The effects of cerivastatin and pravastatin on M-CSF expression were paralleled by similar changes in M-CSF activity. The reduction of M-CSF activity by cerivastatin and pravastatin was completely reversed by cotreatment of HCAECs with L-mevalonate. In the presence of actinomycin D, cerivastatin and pravastatin both altered the post transcriptional stability of the TNF-? and Ox-LDL-induced M-CSF mRNA. Conclusions: Our studies indicate that inhibition of endothelial HMG-CoA reductase downregulates M-CSF expression predominantly by altering the post-transcriptional stability of M-CSF mRNA. Since M-CSF contributes to the pathogenesis of atherosclerosis, these result suggest a novel mechanism whereby statins, by inhibiting the endothelial cell expression of M-CSF contribute to the anti-inflammatory and anti-atherogenic effects of statins. http://www.tkuhn.ch/bel2nanopub/RA20l50oS1xVwEOyXFwn0Y1F3Sax31GfaL6JyEZ74yRJY#_4 http://www.w3.org/ns/prov#wasQuotedFrom http://www.tkuhn.ch/bel2nanopub/RA20l50oS1xVwEOyXFwn0Y1F3Sax31GfaL6JyEZ74yRJY#_3 http://www.tkuhn.ch/bel2nanopub/RA20l50oS1xVwEOyXFwn0Y1F3Sax31GfaL6JyEZ74yRJY#_5 http://www.w3.org/2000/01/rdf-schema#label Selventa http://www.tkuhn.ch/bel2nanopub/RA20l50oS1xVwEOyXFwn0Y1F3Sax31GfaL6JyEZ74yRJY#assertion http://www.w3.org/ns/prov#hadPrimarySource http://www.tkuhn.ch/bel2nanopub/RA20l50oS1xVwEOyXFwn0Y1F3Sax31GfaL6JyEZ74yRJY#_3 http://www.tkuhn.ch/bel2nanopub/RA20l50oS1xVwEOyXFwn0Y1F3Sax31GfaL6JyEZ74yRJY#assertion http://www.w3.org/ns/prov#wasDerivedFrom http://resource.belframework.org/belframework/20131211/knowledge/large_corpus.bel http://www.tkuhn.ch/bel2nanopub/RA20l50oS1xVwEOyXFwn0Y1F3Sax31GfaL6JyEZ74yRJY#assertion http://www.w3.org/ns/prov#wasDerivedFrom http://www.tkuhn.ch/bel2nanopub/RA20l50oS1xVwEOyXFwn0Y1F3Sax31GfaL6JyEZ74yRJY#_4 http://www.tkuhn.ch/bel2nanopub/RA20l50oS1xVwEOyXFwn0Y1F3Sax31GfaL6JyEZ74yRJY#pubinfo http://www.tkuhn.ch/bel2nanopub/RA20l50oS1xVwEOyXFwn0Y1F3Sax31GfaL6JyEZ74yRJY http://purl.org/dc/terms/created 2014-07-03T14:31:29.316+02:00 http://www.tkuhn.ch/bel2nanopub/RA20l50oS1xVwEOyXFwn0Y1F3Sax31GfaL6JyEZ74yRJY http://purl.org/pav/createdBy http://orcid.org/0000-0001-6818-334X http://www.tkuhn.ch/bel2nanopub/RA20l50oS1xVwEOyXFwn0Y1F3Sax31GfaL6JyEZ74yRJY http://purl.org/pav/createdBy http://orcid.org/0000-0002-1267-0234